STAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial

An investigational combination therapy from Eli Lilly led to significant weight loss in a mid-stage study, but high rates of people stopping the treatment may raise questions about its tolerability.  Lilly, which is racing to bring next-generation obesity drugs to the market, tested different combinations of its blockbuster GLP-1 drug Zepbound with eloralintide, a candidate that targets the amylin hormone, in people with obesity and type 2 diabetes. After 48 weeks, participants who stayed on the...